Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N8E2
UPID:
ZN513_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N8E2; A8K3S5; B7WP71; Q3ZCU1; Q68CJ1; Q86UZ3; Q8NDL8; Q96ML3
Background:
Zinc finger protein 513 plays a pivotal role in retinal development and maintenance, acting as a transcriptional regulator. This protein's involvement in the intricate processes of the eye underscores its importance in visual function.
Therapeutic significance:
Linked to Retinitis pigmentosa 58, a condition characterized by night vision blindness and progressive loss of visual field, Zinc finger protein 513's role in this disease highlights its potential as a target for therapeutic intervention.